NMO spectrum disorders and anti AQP4 antibody

Brain and Nerve

Volumn 65, Issue 4, 2013, Pages 333-343

  Takai, Yoshiki ^a   Misu, Tatsuro ^a   Takahashi, Toshiyuki ^a,b   Nakashima, Ichiro ^a   Fujihara, Kazuo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Yonezawa National Hospital   (Japan)

Author keywords

Aquaporin 4 (AQP4); Multiple sclerosis; Neuromyelitis optica (NMO); NMO IgG; NMOsd

Indexed keywords

AQUAPORIN 4 ANTIBODY; BETA INTERFERON; FINGOLIMOD; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYELIN BASIC PROTEIN;

ARTICLE; ASTROCYTE; BRAIN DAMAGE; CEREBROSPINAL FLUID; COMPLEMENT ACTIVATION; DRUG MEGADOSE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PLASMAPHERESIS; PROTEIN EXPRESSION; SPINAL CORD LESION;

ANIMALS; AQUAPORIN 4; AUTOANTIBODIES; DISEASE MODELS, ANIMAL; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA;

EID: 84876303005     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Devic E: Myelite subaiquë compliquée de névrite optique. Bull Med 8: 1033-1034, 1894
2. Gault F: De la neuromyélite optique aiguë [Thesis]. Lyon, 1894
3. NO To Shinkei 53: 901-910, 2001
4. Mandler RN, Davis LE, Jeffery DR, Kornfeld M: Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 34: 162-168, 1993 (Pubitemid 23223043)
5. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG: The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53: 1107-1114, 1999 (Pubitemid 29442132)
6. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG: Revised diagnostic criteria for neuromyelitis optica. Neurology 66: 1485-1489, 2006 (Pubitemid 43958540)
7. Fukazawa T, Kikuchi S, Sasaki H, Hamada K, Hamada T, et al: Anti-nuclear antibodies and the optic-spinal form of multiple sclerosis. J Neurol 244: 483-488, 1997 (Pubitemid 27424785)
8. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, et al: A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125: 1450-1461, 2002 (Pubitemid 34755161)
9. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, et al: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106-2112, 2004 (Pubitemid 39626806)
10. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202: 473-477, 2005 (Pubitemid 41186945)
11. Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P, et al: Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci 17: 171-180, 1997 (Pubitemid 27008860)
12. Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, et al: Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130: 1224-1234, 2007 (Pubitemid 47355951)
13. Parratt JD, Prineas JW: Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes. Mult Scler 16: 1156-1172, 2010
14. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, et al: Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 75: 208-216, 2010
15. Verkman AS: Aquaporins in clinical medicine. Annu Rev Med 63: 303-316, 2012
16. Manley GT, Fujimura M, Ma T, Noshita N, Filiz F, et al: Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med 6: 159-163, 2000 (Pubitemid 30082359)
17. Papadopoulos MC, Manley GT, Krishna S, Verkman AS: Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J 18: 1291-1293, 2004 (Pubitemid 39561580)
18. Bloch O, Auguste KI, Manley GT, Verkman AS: Accelerated progression of kaolin-induced hydrocephalus in aquaporin-4-deficient mice. J Cereb Blood Flow Metab 26: 1527-1537, 2006 (Pubitemid 44809082)
19. Crane JM, Lam C, Rossi A, Gupta T, Bennett JL, et al: Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1/M23 isoforms and orthogonal arrays. J Biol Chem 286: 16516-16524, 2011
20. Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, et al: Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69: 2221-2231, 2007 (Pubitemid 350294677)
21. Kinoshita M, Nakatsuji Y, Moriya M, Okuno T, Kumanogoh A, et al: Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport 20: 508-512, 2009
22. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, et al: Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133: 349-361, 2010
23. Ratelade J, Zhang H, Saadoun S, Bennett JL, Papadopoulos MC, et al: Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol 123: 861-872, 2012
24. Phuan PW, Ratelade J, Rossi A, Tradtrantip L, Verkman AS: Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays. J Biol Chem 287: 13829-13839, 2012
25. Zhang H, Bennett JL, Verkman AS: Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol 70: 943-954, 2011
26. Magaña SM, Matiello M, Pittock SJ, McKeon A, Lennon VA, et al: Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 72: 712-717, 2009
27. Hinson SR, Romero MF, Popescu BF, Lucchinetti CF, Fryer JP, et al: Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A 109: 1245-1250, 2012
28. Rossi A, Ratelade J, Papadopoulos MC, Bennett JL, Verkman AS: Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1/M23 isoform content, or supramolecular assembly. Glia 60: 2027-2039, 2012
29. Hinson SR, Roemer SF, Lucchinetti CF, Fryer JP, Kryzer TJ, et al: Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 205: 2473-2481, 2008
30. Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, et al: Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66: 630-643, 2009
31. Kinoshita M, Nakatsuji Y, Kimura T, Moriya M, Takata K, et al: Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigenspecific T cells. Biochem Biophys Res Commun 394: 205-210, 2010
32. Fujihara K: Neuromyelitis optica and astrocytic damage in its pathogenesis. J Neurol Sci 306: 183-187, 2011
33. Fujihara K, Misu T, Nakashima I, Takahashi T, Bradl M, et al: Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol 3: 58-73, 2012
34. Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, et al: Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130: 1194-1205, 2007 (Pubitemid 47355941)
35. Tanaka M, Tanaka K, Komori M: Interferon-beta(1b) treatment in neuromyelitis optica. Eur Neurol 62: 167-170, 2009
36. Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, et al: Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 69: 239-245, 2012
37. Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, et al: Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 13: 968-974, 2007 (Pubitemid 351541430)
38. Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, et al: Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 13: 128-132, 2007 (Pubitemid 46152772)
39. Mandler RN, Ahmed W, Dencoff JE: Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 51: 1219-1220, 1998 (Pubitemid 28473439)
40. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ: Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 68: 1412-1420, 2011
41. Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, et al: Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 108: 3701-3706, 2011
42. Ayzenberg I, Kleiter I, Schröder A, Hellwig K, Chan A, et al: Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 70: 394-397, 2013
43. Tradtrantip L, Zhang H, Saadoun S, Phuan PW, Lam C, et al: Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 71: 314-322, 2012
44. Paty DW, Oger JJ, Kastrukoff LF, Hashimoto SA, Hooge JP, et al: MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 38: 180-185, 1988 (Pubitemid 18036832)
45. Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, et al: Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 59: 566-569, 2006 (Pubitemid 43358081)
46. Waters P, Vincent A: Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J 15: 99-105, 2008